旗下减肥药宣传内容遭FDA警告 Hims & Hers Health(HIMS.US)跌超7%

Core Viewpoint - Hims&Hers Health's stock price declined over 7% to $49.99 following a formal warning from the FDA regarding the promotion of its compounded semaglutide product, which has not been approved by the agency [1] Regulatory Issues - The FDA emphasized that the compounded drug product is not equivalent to standard medications that have undergone clinical trials and approval [1] - Hims&Hers is required to submit corrective actions within 15 business days, or it may face legal sanctions including product seizures and injunctions [1]